Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Plus Therapeutics

Nasdaq:PSTV
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PSTV
Nasdaq
$6M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Plus Therapeutics has significant price volatility in the past 3 months.
PSTV Share Price and Events
7 Day Returns
-0.7%
NasdaqCM:PSTV
2.5%
US Biotechs
-2%
US Market
1 Year Returns
-90.6%
NasdaqCM:PSTV
-0.9%
US Biotechs
-15.1%
US Market
PSTV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Plus Therapeutics (PSTV) -0.7% -27.8% -42.8% -90.6% -99.8% -100%
US Biotechs 2.5% -8.3% -4.1% -0.9% 10.9% -11.6%
US Market -2% -19.7% -23.2% -15.1% 3.7% 14.4%
1 Year Return vs Industry and Market
  • PSTV underperformed the Biotechs industry which returned -0.9% over the past year.
  • PSTV underperformed the Market in United States of America which returned -15.1% over the past year.
Price Volatility
PSTV
Industry
5yr Volatility vs Market

Value

 Is Plus Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Plus Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $1.43.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Plus Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Plus Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:PSTV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.77
NasdaqCM:PSTV Share Price ** NasdaqCM (2020-04-03) in USD $1.43
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.85x
United States of America Market PE Ratio Median Figure of 2,947 Publicly-Listed Companies 12.4x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Plus Therapeutics.

NasdaqCM:PSTV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:PSTV Share Price ÷ EPS (both in USD)

= 1.43 ÷ -2.77

-0.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Plus Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Plus Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Plus Therapeutics's expected growth come at a high price?
Raw Data
NasdaqCM:PSTV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-43.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.89x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Plus Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Plus Therapeutics's assets?
Raw Data
NasdaqCM:PSTV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.30
NasdaqCM:PSTV Share Price * NasdaqCM (2020-04-03) in USD $1.43
United States of America Biotechs Industry PB Ratio Median Figure of 430 Publicly-Listed Biotechs Companies 2.48x
United States of America Market PB Ratio Median Figure of 5,144 Publicly-Listed Companies 1.2x
NasdaqCM:PSTV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:PSTV Share Price ÷ Book Value per Share (both in USD)

= 1.43 ÷ 0.30

4.78x

* Primary Listing of Plus Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Plus Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Plus Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Plus Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Plus Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-43.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Plus Therapeutics expected to grow at an attractive rate?
  • Unable to compare Plus Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Plus Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Plus Therapeutics's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:PSTV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:PSTV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -43.5%
NasdaqCM:PSTV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -150%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:PSTV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:PSTV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 -11 -12 1
2020-12-31 0 -11 -12 1
2020-04-04
NasdaqCM:PSTV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -6 -4
2019-09-30 10 -9 -11
2019-06-30 6 -10 -14
2019-03-31 6 -11 -14
2018-12-31 7 -12 -15
2018-09-30 4 -14 -18
2018-06-30 5 -15 -19
2018-03-31 6 -17 -24
2017-12-31 6 -18 -27
2017-09-30 8 -18 -23
2017-06-30 9 -19 -24
2017-03-31 10 -19 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Plus Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Plus Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:PSTV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Plus Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:PSTV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -2.98 -2.98 -2.98 1.00
2020-12-31 -3.01 -3.01 -3.01 1.00
2020-04-04
NasdaqCM:PSTV Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.77
2019-09-30 -22.13
2019-06-30 -46.11
2019-03-31 -59.74
2018-12-31 -86.98
2018-09-30 -140.93
2018-06-30 -187.85
2018-03-31 -281.77
2017-12-31 -411.59
2017-09-30 -426.23
2017-06-30 -501.56
2017-03-31 -615.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Plus Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Plus Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Plus Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Plus Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Plus Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Plus Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Plus Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Plus Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Plus Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Plus Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:PSTV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 7.00 -3.84 5.29 5.37
2019-09-30 10.19 -10.52 7.34
2019-06-30 5.88 -14.38 7.60
2019-03-31 6.45 -13.86 7.97
2018-12-31 6.65 -15.12 8.36
2018-09-30 3.80 -17.62 7.37
2018-06-30 5.12 -18.54 7.97
2018-03-31 6.45 -23.53 10.46
2017-12-31 6.41 -26.66 11.19
2017-09-30 7.91 -23.32 11.26
2017-06-30 8.75 -23.90 12.07
2017-03-31 10.07 -24.25 11.90
2016-12-31 11.38 -22.05 12.17
2016-09-30 11.73 -19.89 12.07
2016-06-30 11.60 -12.98 12.18
2016-03-31 12.23 -2.13 12.41
2015-12-31 11.66 -19.41 12.43
2015-09-30 12.05 -23.57 13.63
2015-06-30 10.68 -34.48 16.34
2015-03-31 8.51 -50.76 19.43
2014-12-31 7.60 -38.54 22.36
2014-09-30 7.29 -41.65 24.83
2014-06-30 8.90 -37.53 25.30
2014-03-31 9.87 -28.91 25.22
2013-12-31 12.20 -26.18 25.06
2013-09-30 16.06 -19.96 24.94
2013-06-30 14.67 -25.95 25.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Plus Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Plus Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Plus Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Plus Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Plus Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Plus Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Plus Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Plus Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Plus Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Plus Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Plus Therapeutics Company Filings, last reported 3 months ago.

NasdaqCM:PSTV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1.16 11.06 17.55
2019-09-30 0.16 10.79 16.83
2019-06-30 -6.28 10.69 4.53
2019-03-31 3.86 14.24 3.87
2018-12-31 5.23 14.20 5.26
2018-09-30 6.14 14.01 6.81
2018-06-30 4.75 13.84 3.08
2018-03-31 8.48 13.73 5.90
2017-12-31 13.00 13.62 9.55
2017-09-30 7.82 13.50 4.78
2017-06-30 11.23 14.52 9.03
2017-03-31 7.36 16.09 6.26
2016-12-31 10.99 17.64 12.56
2016-09-30 13.67 17.40 14.92
2016-06-30 18.72 17.16 20.04
2016-03-31 7.74 16.92 9.36
2015-12-31 12.21 16.68 14.34
2015-09-30 5.00 16.42 18.97
2015-06-30 2.26 16.21 23.84
2015-03-31 -23.20 25.68 13.20
2014-12-31 -5.70 25.40 14.62
2014-09-30 -3.29 25.81 7.85
2014-06-30 1.19 26.84 12.76
2014-03-31 2.40 26.57 12.80
2013-12-31 3.13 26.29 15.51
2013-09-30 -3.19 26.02 10.21
2013-06-30 1.26 25.74 13.62
  • Plus Therapeutics's level of debt (953.4%) compared to net worth is high (greater than 40%).
  • Plus Therapeutics had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Plus Therapeutics has sufficient cash runway for 2.9 years based on current free cash flow.
  • Plus Therapeutics has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -21.2% each year.
X
Financial health checks
We assess Plus Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Plus Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Plus Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Plus Therapeutics dividends.
If you bought $2,000 of Plus Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Plus Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Plus Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:PSTV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 66 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1938 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2.1%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:PSTV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-04

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Plus Therapeutics has not reported any payouts.
  • Unable to verify if Plus Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Plus Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Plus Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Plus Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Plus Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Plus Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Plus Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marc Hedrick
COMPENSATION $614,978
AGE 56
TENURE AS CEO 6 years
CEO Bio

Dr. Marc H. Hedrick, M.D., has been the President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc. and Macropore Biosurgery Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr. Hedrick had been Principal Financial and Accounting Officer at Plus Therapeutics, Inc. since August 09, 2019 until November 6, 2019. Dr. Hedrick served as the Principal Financial Officer of Cytori Therapeutics, Inc. from August 2014 to September 2, 2014. Dr. Hedrick joined Cytori Therapeutics, Inc. as the Chief Scientific Officer and Medical Director in October 2002. He co-founded StemSource Inc. and served as the President and Chief Executive Officer and Director. He is a Plastic Surgeon and was an Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA) and From 1998 to 2005, has directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick has been a Director of Cytori Therapeutics, Inc. since October 2002. He obtained his MD degree from the University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management.

CEO Compensation
  • Marc's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Marc's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Plus Therapeutics management team in years:

0.6
Average Tenure
56
Average Age
  • The average tenure for the Plus Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Marc Hedrick

TITLE
President
COMPENSATION
$615K
AGE
56
TENURE
6 yrs

Andrew Sims

TITLE
VP of Finance & CFO
AGE
45
TENURE
0.2 yrs

Desiree Smith

TITLE
Corporate Controller
AGE
55
TENURE
0.4 yrs

John Fraser

TITLE
Chief Scientist
AGE
58

Russ Havranek

TITLE
Vice President of Marketing

Gary Titus

TITLE
AGE
59
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Plus Therapeutics board of directors in years:

1.3
Average Tenure
57.5
Average Age
  • The average tenure for the Plus Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rick Hawkins

TITLE
Independent Chairman of the Board
COMPENSATION
$50K
AGE
70
TENURE
2.3 yrs

Marc Hedrick

TITLE
President
COMPENSATION
$615K
AGE
56
TENURE
17.5 yrs

An van Es-Johansson

TITLE
Independent Director
AGE
59
TENURE
0.3 yrs

Greg Petersen

TITLE
Independent Director
AGE
56
TENURE
0.2 yrs

Robert Lenk

TITLE
Independent Director

Howard Clowes

TITLE
Independent Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Plus Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Plus Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company’s lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi’s sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Details
Name: Plus Therapeutics, Inc.
PSTV
Exchange: NasdaqCM
Founded: 1996
$5,549,240
3,880,588
Website: http://www.plustherapeutics.com
Address: Plus Therapeutics, Inc.
4200 Marathon Boulevard,
Suite 200,
Austin,
Texas, 78756,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM PSTV Common Stock Nasdaq Capital Market US USD 10. Aug 2000
DB XMPA Common Stock Deutsche Boerse AG DE EUR 10. Aug 2000
LSE 0I5U Common Stock London Stock Exchange GB USD 10. Aug 2000
Number of employees
Current staff
Staff numbers
37
Plus Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 07:33
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.